Clinical Trial Update: A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety and hepatic hemodynamic effects of intravenous conivaptan in patients with liver cirrhosis; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis

Drugs mentioned

• Conivaptan (conivaptan)

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Liver Cirrhosis | Phase 2 | Status: COMPLETED | Results posted: 2010-09-28